Avalo Therapeutics (AVTX) – Analysts’ Weekly Ratings Changes

Avalo Therapeutics (NASDAQ: AVTX) recently received a number of ratings updates from brokerages and research firms:

• 8/16/2026 – Avalo Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/11/2026 – Avalo Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/8/2026 – Avalo Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Avalo Therapeutics was given a new $48.00 price target by Guggenheim. They now have a “buy” rating on the stock.
• 8/7/2026 – Avalo Therapeutics had its price target lowered by HC Wainwright from $35.00 to $30.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Avalo Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/6/2026 – Avalo Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $38.00 price target on the stock.
• 6/30/2026 – Avalo Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.